Document:

Assignment by and between KUDOS Pharmaceuticals Limited and Novacea Inc.

 Exhibit 10.3 
 ASSIGNMENT 
 by and between 
 KUDOS PHARMACEUTICALS LIMITED 
 and 
 NOVACEA, INC. 
 DATE:
        19 April 2007 

 TABLE OF CONTENTS 
  

					
			
	1	 	Definitions	  	1
			
	2	 	Assignment	  	2
			
	3	 	Payment Terms	  	2
			
	4	 	Transfer Obligations	  	3
			
	5	 	Material Agreements	  	3
			
	6	 	Further Action	  	2
			
	7	 	Limitations	  	3
			
	8	 	Indemnity	  	4
			
	9	 	Counterparts	  	5

 Schedule 1 - Assigned Patents 
 Schedule 2 - Assigned Know-How 
 Schedule 3 - Material Agreements 
 Schedule 4 - Ongoing Studies 
  

 ASSIGNMENT 
 This Assignment of patent rights and other intellectual property (this “Assignment”) is made as of the 19th day of April, 2007 by and between 
  

	(1)	KuDOS PHARMACEUTICALS LIMITED, a company incorporated in England under no. 03479984 whose registered office is at 15 Stanhope Gate, London, W1K 1LN
(“KuDOS”); and 

  

	(2)	NOVACEA, INC., a company incorporated in Delaware having its principal place of business at 601 Gateway Boulevard, Suite 801, South San Francisco, CA 94080
(“Novacea”). 

 Recitals 
  

	(A)	WHEREAS, KuDOS is the owner of the rights, title and interest in the Assigned Patents and the Assigned Know-How. 

  

	(B)	WHEREAS, Novacea wishes to acquire the entire rights, title and interest in and to the Assigned Patents and Assigned Know-How, respectively. 

 Agreement 
 NOW, THEREFORE, in consideration of the mutual
covenants contained in this Assignment, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, agree as follows: 
  

	1	Definitions 

 Unless otherwise specifically
provided in this Assignment, the following terms shall have the following meanings: 
  

	1.1	“Assigned Know-How” means the intellectual property and materials arising from the Sub-Licence Agreement, as described in Schedule 2 attached hereto.

  

	1.2	“Assigned Patents” means: (i) those patents and patent applications set out in Schedule 1 attached hereto; and (ii) all patents issuing from such patent
applications, divisionals, continuations, continuations-in-part, reissues, re-examinations, renewals, extensions, utility models, additions and supplementary protection certificates to any such patents or patent applications;

  

 1 

	1.3	“Effective Date” has the meaning set out in clause 9; 

  

	1.4	“Material Agreements” means those agreements listed in Schedule 3 attached hereto; 

  

	1.5	“Sub-Licence Agreement” means the sub-licence agreement dated 3 December 2003 between Novacea and KuDOS relating to the product defined therein as
“AQ4N.” 

  

	2	Assignment 

 In consideration of the payment
by Novacea to KuDOS of the amounts set out in clause 3, KuDOS hereby irrevocably assigns, sells and transfers to Novacea: 
  

	2.1	all of KuDOS’s right, title and interest in and to the Assigned Patents; 

  

	2.2	all of KuDOS’s right, title and interest in and to the Assigned Know-How; and 

  

	2.3	any and all causes of action, claims, demands or other rights, occasioned from or because of any and all past and future infringement of any of: the Assigned Patents or Assigned
Know-How; including all associated rights to recover damages, profits and injunctive relief for infringement of any of the foregoing. 

  

	3	Payment Terms 

 In consideration of the
assignment by KuDOS of the rights referred to in clause 2, Novacea shall pay to KuDOS: 
 five million US Dollars (USD 5,000,000) within [*]
days following the end of the first calendar year in which [*], as defined in the Sublicense Agreement, [*] exceeds [*] US Dollars (USD [*]). 
  

	4	Further Action  

 KuDOS covenants and agrees,
at the reasonable request of Novacea and at no additional expense to KuDOS to execute and deliver any further documents and to take any further actions reasonably necessary to enable Novacea to become the registered owner of the Assigned Patents and
to secure the benefits of the rights hereby assigned. 
  
 [*] Certain
information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 2 

	5	Material Agreements and Transfer Obligations 

  

	5.1	Ongoing Studies: KuDOS shall conduct and use reasonable endeavours to complete, for the benefit of Novacea, and subject to reasonable input by Novacea, the ongoing studies
listed in Schedule 4 (the “Ongoing Studies”). KuDOS will also use reasonable endeavours to deliver to Novacea, the activities and deliverables listed in Schedule 4. 

  

	5.2	Transfer of Know-How: KuDOS will, for the benefit of Novacea, use reasonable endeavours to deliver to Novacea the Assigned Know-How within 90 days of the signing of this
Assignment. 

  

	5.3	Material Agreements: Novacea has elected to either (i) take an assignment to, or (ii) have terminated, the Material Agreements. KuDOS shall use reasonable
endeavours to conduct and complete those actions indicated in Schedule 3 for the benefit of Novacea, in a timely fashion. Notwithstanding the above, with respect to all Material Agreements, KuDOS will use reasonable endeavours to complete those
actions listed in Schedule 3 within 90 days of the signing of this Assignment. 

  

	6	Limitations 

 Nothing herein shall be
construed as: (a) a warranty, representation or covenant by KuDOS as to the validity, enforceability or priority of invention of the Assigned Patents, or that the Assigned Patents or Assigned Know-How will be free from infringement of patents
or violation of other rights of third parties, (b) conferring on either party a right to use in advertising, publicity or the like any name, trademark or trade name of the other party, (c) an obligation on KuDOS to bring, participate in,
prosecute or settle any actions or suits against third parties for infringement of any of the Assigned Patents or Assigned Know-How. 
  

	7.	Indemnity 

  

	7.1	 KuDOS shall indemnify Novacea against any loss, damages, costs or expenses which are awarded against or incurred by Novacea as a result of (i) any claim or
threatened claim which arises directly or indirectly from negligence or intentional misconduct relating to the conducting or completion of Ongoing Studies subsequent to the applicable Effective 

  

 3 

	 	 
Date in respect of each such matter; and (ii) any material delay in the completion or delivery of items listed in clause 5 (Material Agreements and
Transfer Obligations) and Schedules 1-4, except to the extent that any such claim results from the negligence or intentional misconduct of Novacea. 

  

	7.2	Novacea shall indemnify KuDOS against any loss, damages, costs or expenses which are awarded against or incurred by KuDOS as a result of any claim or threatened claim which arises
directly or indirectly from the development, manufacture, importing, use, storage, marketing, sale or disposal of the Licensed Products (as defined in the Sub-Licence Agreement) or otherwise in relation to the Assigned Patents or Assigned Know-How
which are the subject of this Assignment, subsequent to the applicable Effective Date in respect of each such matter, as specified in clause 9, except to the extent that any such claim results from the negligence or intentional misconduct of KuDOS.

  

	8.	Representations and Warranties 

 KuDOS
represents and warrants that, to the best of its knowledge and belief, the Assigned Patents and Assigned Know-How includes, without limitation, all inventions, discoveries, contracts, reports, agreements, invention disclosures and filings, patent
rights, patent applications, trade secrets and know-how, including without limitation, laboratory scientific information, procedures and techniques, methods, processes, synthetic methodologies, pre-clinical and clinical testing data owned,
developed, or licensed by KuDOS relating to AQ4N. 
  

	9.	Effective Date 

 The Effective Date for the
purposes of this Assignment shall be: 
  

	9.1	in respect of the Assigned Patents, the date of this Assignment; 

  

	9.2	in respect of Assigned Know-How, the date of this Assignment, or, if the transfer of such Assigned Know-How occurs after the date of this Assignment, the date of receipt by Novacea
of such Assigned Know-How; 

  

 4 

	9.3	in respect of each Material Agreement upon completion of the relevant assignment or termination of each such Material Agreement, pursuant to clause 5.3; 

  

	9.4	in respect of each of the Ongoing Studies, upon completion of each such Ongoing Study, pursuant to clause 5.1. 

  

	10.	Counterparts 

 This Assignment may be
executed in any number of counterparts, each of which shall be deemed an original and all of which taken together shall be deemed to constitute one and the same instrument. 
  

	11.	Governing Law and Jurisdiction 

  

	The	interpretation and construction of this Assignment shall be governed by the laws of England, excluding any conflicts or choice of law rule or principle that might otherwise refer
construction or interpretation of this Assignment to the substantive law of another jurisdiction. The parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts of England for any action, suit or proceeding
arising out of or relating to this Assignment, and agree not to commence any action, suit or proceeding related thereto except in such courts. 

  

 5 

 THIS ASSIGNMENT IS EXECUTED by the authorised representatives of the parties as of the date first written above.

  

			
	KUDOS PHARMACEUTICALS LIMITED
		
	 Signature:
	 	 /s/ Anne Brindley

		 	 
		
	 Name:
	 	 Anne Brindley

		
	 Title:
	 	 Global Product Director

		
	 Date:
	 	 19th April 2007

  

			
	NOVACEA, INC.
		
	 Signature:
	 	 /s/ John P. Walker

		 	 
		
	 Name:
	 	 John P. Walker

		
	 Title:
	 	 Chairman-Interim CEO

		
	 Date:
	 	
		 	 

  

 6 

 Schedule 1—Assigned Patents 
 [*] 
  
 [*] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 7 

 Schedule 2—Assigned Know-How 
 [*] 
  
 [*] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 8 

 Schedule 3—Material Agreements 
 [*] 
  
 [*] Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 9 

 Schedule 4—Ongoing Studies 
 Ongoing Studies 
 [*] 
  
 [*] Certain information on this page has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
  

 10Thirteenth Amendment to Loan and Security Agreement

 Exhibit 10.17 
 THIRTEENTH AMENDMENT TO 
 LOAN AND SECURITY AGREEMENT 
 THIS THIRTEENTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of April 20, 2007 by and among TELOS
CORPORATION, a Maryland corporation (“Parent”), XACTA CORPORATION, a Delaware corporation (“Xacta”; Parent and Xacta are referred to hereinafter each individually as a “Borrower”, and individually and
collectively, jointly and severally, as the “Borrowers”), TELOS DELAWARE, INC., a Delaware corporation (“Telos-Delaware”), UBIQUITY.COM, INC., a Delaware corporation (“Ubiquity”), TELOS.COM, INC., a
Delaware corporation (“Telos.com”), TELOS INTERNATIONAL CORP., a Delaware corporation (“TIC”), TELOS INTERNATIONAL ASIA, INC., a Delaware corporation (“TIA”), SECURE TRADE, INC., a Delaware
corporation (“STI”), KUWAIT INTERNATIONAL, INC., a Delaware corporation (“KII”), TELOS INFORMATION SYSTEMS, INC., a Delaware corporation (“TIS”), TELOS FIELD ENGINEERING, INC., a Delaware
corporation (“TFE”), and TELOS FEDERAL SYSTEMS, INC., a Delaware corporation (“TFS”; Telos-Delaware, Ubiquity, Telos.com, TIC, TIA, STI, KII, TIS, TFE and TFS are referred to hereinafter each individually as a “Credit
Party” and collectively, jointly and severally, as the “Credit Parties”), and WELLS FARGO FOOTHILL, INC. (formerly known as Foothill Capital Corporation), as agent (“Agent”) for the Lenders (defined below) and as a
Lender. 
 WHEREAS, Borrowers, Credit Parties, Agent and certain other financial institutions from time to time party thereto (the
“Lenders”) are parties to that certain Loan and Security Agreement dated as of October 21, 2002 (as amended from time to time, the “Loan Agreement”); 
 WHEREAS, subject to the terms and conditions contained herein, Borrowers, Credit Parties, Agent and Lenders have agreed to amend the Loan Agreement in
certain respects. 
 NOW THEREFORE, in consideration of the premises and mutual agreements herein contained, the parties hereto agree as
follows: 
 1. Defined Terms. Unless otherwise defined herein, capitalized terms used herein shall have the meanings ascribed to such
terms in the Loan Agreement. 
 2. Amendments to Loan Agreement. Subject to the satisfaction of the conditions set forth in
Section 4 hereof, the Loan Agreement is amended in the following respect: 
 The definition of “Availability
Block” as set forth in Section 1.1 of the Loan Agreement is amended and restated in its entirety, as follows: 
 “Availability Block” means an amount equal to $500,000; provided, that Availability Block shall mean an amount equal to $0 for the period from October 27, 2006 through and including January 31, 2007. 

 3. Ratification. This Amendment, subject to satisfaction of the conditions set forth in
Section 4 below, shall constitute an amendment to the Loan Agreement and all of the Loan Documents as appropriate to express the agreements contained herein. Except as specifically set forth herein, the Loan Agreement and the Loan Documents
shall remain unchanged and in full force and effect in accordance with their original terms. 
 4. Conditions to Effectiveness. This
Amendment shall become effective retroactive to December 30, 2006 upon the satisfaction of the following conditions precedent: 
 (a)
Each party hereto shall have executed and delivered this Amendment to Agent; 
 (b) Agent shall have received the fee described in
Section 5 hereof; 
 (c) Borrowers shall have delivered to Agent such documents, agreements and instruments as may be requested or
required by Agent in connection with this Amendment, each in form and content acceptable to Agent; 
 (d) No Default or Event of Default
shall have occurred and be continuing on the date hereof or as of the date of the effectiveness of this Amendment; and 
 (e) All proceedings
taken in connection with the transactions contemplated by this Amendment and all documents, instruments and other legal matters incident thereto shall be satisfactory to Agent and its legal counsel. 
 5. Additional Availability Fee. To induce Agent and Lenders to enter into this Amendment, Borrowers shall pay to Agent, for the benefit of
Lenders, a non-refundable fee equal to $10,000, which shall be due and payable on the date hereof. 
 6. Miscellaneous. 
 (a) Warranties and Absence of Defaults. To induce Agent and Lenders to enter into this Amendment, each Company hereby represents and warrants to
Agent and Lenders that: 
 (i) The execution, delivery and performance by it of this Amendment and each of the other
agreements, instruments and documents contemplated hereby are within its corporate power, have been duly authorized by all necessary corporate action, have received all necessary governmental approval (if any shall be required), and do not and will
not contravene or conflict with any provision of law applicable to it, its articles of incorporation and by-laws, any order, judgment or decree of any court or governmental agency, or any agreement, instrument or document binding upon it or any of
its property; 
  

 -2- 

 (ii) Each of the Loan Agreement and the other Loan Documents, as amended by this
Amendment, are the legal, valid and binding obligation of it enforceable against it in accordance with its terms, except as the enforcement thereof may be subject to (A) the effect of any applicable bankruptcy, insolvency, reorganization,
moratorium or similar laws affecting creditor’s rights generally, and (B) general principles of equity; 
 (iii) The
representations and warranties contained in the Loan Agreement and the other Loan Documents are true and accurate as of the date hereof with the same force and effect as if such had been made on and as of the date hereof; and 
 (iv) It has performed all of its obligations under the Loan Agreement and the Loan Documents to be performed by it on or before the date
hereof and as of the date hereof, it is in compliance with all applicable terms and provisions of the Loan Agreement and each of the Loan Documents to be observed and performed by it and no event of default or other event which upon notice or lapse
of time or both would constitute an event of default has occurred. 
 (b) Expenses. Companies, jointly and severally, agree to pay on
demand all costs and expenses of Agent (including the reasonable fees and expenses of outside counsel for Agent) in connection with the preparation, negotiation, execution, delivery and administration of this Amendment and all other instruments or
documents provided for herein or delivered or to be delivered hereunder or in connection herewith. In addition, Companies agree, jointly and severally, to pay, and save Agent harmless from all liability for, any stamp or other taxes which may be
payable in connection with the execution or delivery of this Amendment or the Loan Agreement, as amended hereby, and the execution and delivery of any instruments or documents provided for herein or delivered or to be delivered hereunder or in
connection herewith. All obligations provided herein shall survive any termination of the Loan Agreement as amended hereby. 
 (c)
Governing Law. This Amendment shall be a contract made under and governed by the internal laws of the State of Illinois. 
 (d)
Counterparts. This Amendment may be executed in any number of counterparts, and by the parties hereto on the same or separate counterparts, and each such counterpart, when executed and delivered, shall be deemed to be an original, but all
such counterparts shall together constitute but one and the same Amendment. 
 7. Release. 
 (a) In consideration of the agreements of Agent and Lenders contained herein and for other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, each Company, on behalf of itself and its successors, assigns, and 

  

 -3- 

 
other legal representatives, hereby absolutely, unconditionally and irrevocably releases, remises and forever discharges Agent and Lenders, and their
successors and assigns, and their present and former shareholders, affiliates, subsidiaries, divisions, predecessors, directors, officers, attorneys, employees, agents and other representatives (Agent, each Lender and all such other Persons being
hereinafter referred to collectively as the “Releasees” and individually as a “Releasee”), of and from all demands, actions, causes of action, suits, covenants, contracts, controversies, agreements, promises, sums of money,
accounts, bills, reckonings, damages and any and all other claims, counterclaims, defenses, rights of set-off, demands and liabilities whatsoever (individually, a “Claim” and collectively, “Claims”) of every name and nature,
known or unknown, suspected or unsuspected, both at law and in equity, which such Company or any of its successors, assigns, or other legal representatives may now or hereafter own, hold, have or claim to have against the Releasees or any of them
for, upon, or by reason of any circumstance, action, cause or thing whatsoever which arises at any time on or prior to the day and date of this Amendment, including, without limitation, for or on account of, or in relation to, or in any way in
connection with any of the Loan Agreement, or any of the other Loan Documents or transactions thereunder or related thereto. 
 (b) Each
Company understands, acknowledges and agrees that the release set forth above may be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted
or attempted in breach of the provisions of such release. 
 (c) Each Company agrees that no fact, event, circumstance, evidence or
transaction which could now be asserted or which may hereafter be discovered shall affect in any manner the final, absolute and unconditional nature of the release set forth above. 
 [signature pages follow] 
  

 -4- 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be executed by their respective
officers thereunto duly authorized and delivered as of the date first above written. 
  

			
	BORROWERS:
	
	 TELOS CORPORATION,
 a Maryland
corporation

		
	By	 	 /s/ Michael P. Flaherty

	Title	 	  

	
	 XACTA CORPORATION,
 a Delaware
corporation

		
	By	 	 /s/ Michael P. Flaherty

	Title	 	  

	
	CREDIT PARTIES:
	
	 TELOS DELAWARE, INC.,
 a
Delaware corporation

		
	By	 	 /s/ Michael P. Flaherty

	Title	 	  

	
	 UBIQUITY.COM, INC.,
 a Delaware
corporation

		
	By	 	 /s/ Michael P. Flaherty

	Title	 	  

 Signature Page to Thirteenth Amendment to Loan and Security Agreement 

			
	TELOS.COM, INC.,
	a Delaware corporation
		
	By	 	 /s/ Michael P. Flaherty

	Title	 	  

	
	 TELOS INTERNATIONAL CORP.,
 a Delaware
corporation

		
	By	 	 /s/ Michael P. Flaherty

	Title	 	  

	
	 TELOS INTERNATIONAL ASIA, INC.,
 a
Delaware corporation

		
	By	 	 /s/ Michael P. Flaherty

	Title	 	  

	
	 SECURE TRADE, INC.,
 a Delaware
corporation

		
	By	 	 /s/ Michael P. Flaherty

	Title	 	  

	
	KUWAIT INTERNATIONAL, INC.,
	a Delaware corporation
		
	By	 	 /s/ Michael P. Flaherty

	Title	 	  

 Signature Page to Thirteenth Amendment to Loan and Security Agreement 

			
	TELOS INFORMATION SYSTEMS, INC.,
	a Delaware corporation
		
	By	 	 /s/ Michael P. Flaherty

	Title	 	  

	
	 TELOS FIELD ENGINEERING, INC.,
 a
Delaware corporation

		
	By	 	 /s/ Michael P. Flaherty

	Title	 	  

	
	 TELOS FEDERAL SYSTEMS, INC.,
 a
Delaware corporation

		
	By	 	 /s/ Michael P. Flaherty

	Title	 	  

	
	AGENT AND LENDER:
	
	WELLS FARGO FOOTHILL, INC. (formerly known as Foothill Capital Corporation)
		
	By	 	 /s/ David Sanchez

	Title	 	V.P.

 Signature Page to Thirteenth Amendment to Loan and Security Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]